Panel Details:
Event:
Title:
Date/Time:
A webcast of the panel discussion may be accessed on the Events & Presentations page under the Investors & Media section of
About
RCC is a cough lasting more than 8 weeks despite appropriate treatment for underlying condition(s). It is estimated that there are approximately 9 million patients in
The Company is exploring the potential use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220301005476/en/
Chief Financial Officer
rbenamar@bellushealth.com
Media:
Solebury Trout
jdeutsch@soleburytrout.com
Source: